MEN1 and acute myeloid leukemia: So far, the development of Menin inhibitors has followed a textbook path that may serve as a role model for future drug developments in oncology: Unlike many other examples in modern oncology, Menin inhibitors entered clinical phase‐I trials after a very detailed preclinical characterization that concisely defined sensitive AML subtypes as well as synergistic drug combination partners.